Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Katri Koli"'
Autor:
Eva Sutinen, Henrik Wolff, Jari Räsänen, Tapio Vehmas, Katri Koli, Eeva Kuosma, Sanna Laaksonen, Jarmo A. Salo, Kirsti Husgafvel-Pursiainen, Ilkka Ilonen, Marjukka Myllärniemi
Publikováno v:
Acta Oncologica. 58:38-44
Background: Malignant pleural mesothelioma (MPM) is a rare occupational cancer with a poor prognosis. Even with a multimodality treatment approach, the treatment outcomes remain unsatisfactory. The use of asbestos has been banned in most developed co
Autor:
Mayank Saraswat, Katri Koli, Eva Sutinen, Risto Renkonen, Ville Vartiainen, Tiialotta Tohmola, Sakari Joenväärä, Marjukka Myllärniemi
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Idiopathic pulmonary fibrosis (IPF) is a lung parenchymal disease of unknown cause usually occurring in older adults. It is a chronic and progressive condition with poor prognosis and diagnosis is largely clinical. Currently, there exist few biomarke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b996f2c5dcb8f759df60cdde4923f3
http://hdl.handle.net/10138/319352
http://hdl.handle.net/10138/319352
Autor:
Norbert Weissmann, Susan Scheibe, Katri Koli, Harald von Melchner, Martin Serchinger, Ana Tomasovic, Silke De-Zolt, Duran Sürün, Anja Sterner-Kock, Nina Kurrle, Frank Schnütgen, Frank Wempe
Publikováno v:
Matrix Biology. 59:109-120
Latent transforming growth factor beta binding protein 4 (LTBP4) belongs to the fibrillin/LTBP family of proteins and plays an important role as a structural component of extracellular matrix (ECM) and local regulator of TGF beta signaling. We have p
Autor:
Hannu Kankaanranta, Eija-Riitta Salomaa, Katri Koli, Riitta Kaarteenaho, Ulla Hodgson, Tero Vahlberg, Jaana Kaunisto, Marjukka Myllärniemi
Publikováno v:
ERJ Open Research, Vol 5, Iss 3 (2019)
ERJ Open Research
ERJ Open Research
Idiopathic pulmonary fibrosis (IPF) is characterised by unpredictable disease course and poor survival. After the introduction of novel antifibrotic drugs, the prognosis of patients with IPF is probably changing. FinnishIPF, a nationwide registry of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408a496a8e3bb18ddd93fa7a7bd83a51
http://hdl.handle.net/10138/313003
http://hdl.handle.net/10138/313003
Autor:
Katri Koli, HP Laurila, Mari Palviainen, Minna M. Rajamäki, Eva Sutinen, Pernilla Syrjä, Liisa Lilja-Maula, Olli Ritvos, Marjukka Myllärniemi
Publikováno v:
Journal of Comparative Pathology. 152:192-200
Activins, cytokines belonging to the transforming growth factor-β superfamily, have an important role in inflammation and fibrosis. Activin A has been suggested to participate in the pathophysiology of human idiopathic pulmonary fibrosis (IPF), but
Autor:
Petra Sipilä, Marjukka Myllärniemi, Pia Rantakari, Katri Koli, Dario Greco, Eva Sutinen, Mikko Rönty, Ville Pulkkinen, Vittorio Fortino
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 7, p e0159010 (2016)
PLoS ONE, Vol 11, Iss 7, p e0159010 (2016)
Idiopathic pulmonary fibrosis (IPF) is characterized by activation and injury of epithelial cells, the accumulation of connective tissue and changes in the inflammatory microenvironment. The bone morphogenetic protein (BMP) inhibitor protein gremlin-
Autor:
Esko I. Kauppinen, Amanda Attobrah, Katri Koli, Marjukka Myllärniemi, Ville Vartiainen, Janne Raula
Publikováno v:
QJM: An International Journal of Medicine.
Idiopathic pulmonary fibrosis (IPF) is a severe progressive fibrotic lung disease. During the past few years two orally administered drug candidates (pirfenidone and nintedanib) for slowing the progression of IPF were approved for clinical practice.
Autor:
Katri Koli, Outi Leppäranta, Marjukka Myllärniemi, Jorma Keski-Oja, Vuokko L. Kinnula, Kaisa Salmenkivi, Carla Sens
Publikováno v:
Cell and Tissue Research. 348:491-503
Idiopathic pulmonary fibrosis (IPF) is a progressive disease of unknown cause. The pathogenesis of the disease is characterized by fibroblast accumulation and excessive transforming growth factor-β (TGF-β) activation. Although TGF-β activation is
Autor:
Vuokko L. Kinnula, Jorma Keski-Oja, Marjukka Myllärniemi, Katri Koli, Kaisa Salmenkivi, T. Aine, Kirsi Vuorinen, Hannu Kankaanranta, Ville Pulkkinen
Publikováno v:
The Journal of Pathology. 214:456-463
Idiopathic pulmonary fibrosis (IPF) (histopathology of usual interstitial pneumonia, UIP) and non-specific interstitial pneumonia (NSIP) are diseases characterized by loss of normal lung architecture and function. The differential diagnosis between I
Autor:
Kaisa Salmenkivi, Kirsi Vuorinen, Merja Johanna Ryynänen, Katri Koli, Vuokko L. Kinnula, Jorma Keski-Oja, Marjukka Myllärniemi
Publikováno v:
The American Journal of Pathology. 169:61-71
Idiopathic pulmonary fibrosis (IPF), ie, usual interstitial pneumonia in histopathology, is a disease characterized by tissue destruction and active areas of fibroproliferation in the lung. Gremlin (Drm), a member of the cysteine knot family of bone